ADAM10 Regulates Endothelial Permeability and T-Cell Transmigration by Proteolysis of Vascular Endothelial Cadherin

Beate Schulz,* Jessica Pruessmeyer,* Thorsten Maretzky, Andreas Ludwig, Carl P. Blobel, Paul Saftig, Karina Reiss

Abstract—Vascular endothelial (VE)-cadherin is the major adhesion molecule of endothelial adherens junctions. It plays an essential role in controlling endothelial permeability, vascular integrity, leukocyte transmigration, and angiogenesis. Elevated levels of soluble VE-cadherin are associated with diseases like coronary atherosclerosis. Previous data showed that the extracellular domain of VE-cadherin is released by an unknown metalloprotease activity during apoptosis. In this study, we used gain-of-function analyses, inhibitor studies, and RNA interference experiments to analyze the proteolytic release of VE-cadherin in human umbilical vein endothelial cells (HUVECs). We found that VE-cadherin is specifically cleaved by the disintegrin and metalloprotease ADAM10 in its ectodomain, releasing a soluble fragment and generating a carboxyl-terminal membrane-bound stub, which is a substrate for a subsequent γ-secretase cleavage. This ADAM10-mediated proteolysis could be induced by Ca²⁺ influx and staurosporine treatment, indicating that ADAM10-mediated VE-cadherin cleavage contributes to the dissolution of adherens junctions during endothelial cell activation and apoptosis, respectively. In contrast, protein kinase C activation or inhibition did not modulate VE-cadherin processing. Increased ADAM10 expression was functionally associated with an increase in endothelial permeability. Remarkably, our data indicate that ADAM10 activity also contributes to the thrombin-induced decrease of endothelial cell–cell adhesion. Moreover, knockdown of ADAM10 in HUVECs as well as in T cells by small interfering RNA impaired T-cell transmigration. Taken together, our data identify ADAM10 as a novel regulator of vascular permeability and demonstrate a hitherto unknown function of ADAM10 in the regulation of VE-cadherin–dependent endothelial cell functions and leukocyte transendothelial migration. (Circ Res. 2008;102:1192-1201.)

Key Words: endothelium • metalloprotease • endothelial permeability • VE-cadherin

The endothelium represents the major physical barrier in the extravasation of blood components and leukocytes to the surrounding tissue. Impairment of this barrier by inflammatory mediators leads to disintegration of endothelial junctions and an increase in permeability and formation of edema. However, the molecular mechanisms regulating the cohesion of endothelial junctions are still poorly understood. Vascular endothelial (VE)-cadherin, which represents the major component of endothelial adherens junctions, is a crucial determinant of vascular integrity. This 130-kDa cell surface glycoprotein that mediates homotypic Ca²⁺-dependent cell adhesion also plays a central role in vasculogenesis, angiogenesis, and the regulation of macromolecular permeability. Several inflammatory mediators and vasoactive factors, including thrombin, have the potential to disrupt the VE-cadherin complex and to increase vascular permeability providing the basis of edematous tissue injury in many diseases states including sepsis, ischemia/reperfusion, and acute respiratory distress.

The vascular endothelium also forms an important barrier for circulating leukocytes. Endothelial cells actively control the efficiency of leukocyte transmigration by regulating the structure of intercellular junctions. It has been proposed that VE-cadherin acts as a gatekeeper for the passage of leukocytes, which induce delocalization of VE-cadherin away from adherens junctions. Recently, it was shown that the extracellular domain of VE-cadherin is released by an unidentified metalloprotease activity during apoptosis of endothelial cells, suggesting that shedding of VE-cadherin may play a role in several biological settings that involve reorganization of adherens junctions. Moreover, elevated levels of soluble VE-cadherin and increased VE-cadherin processing are associated with coronary atherosclerosis and diabetic retinopathy. These findings suggest that the proteolytic release of...
VE-cadherin represents an important mechanism for the regulation of VE-cadherin functions. However, the protease responsible for this process has not been identified.

The majority of ectodomain sheddases belong to the family of zinc-dependent transmembrane disintegrin metalloproteinases (ADAMs [a disintegrin and metalloproteinase]). ADAMs play an important role in diverse biological processes, such as fertilization, myogenesis, neurogenesis, and the activation of growth factors and immune regulators. Several ADAMs have been implicated in the development of the cardiovascular system and the remodeling of cardiac tissue. In particular, ADAM10 and its close relative ADAM17 (tumor necrosis factor [TNF]-α–converting enzyme [TACE]) have been studied in the context of ectodomain shedding. Disruption of ADAM17 in mice results in perinatal lethality. The mice show similar heart defects as heparin-binding epidermal growth factor–like growth factor (HB-EGF)–deficient mice, probably because of the role of ADAM17 for processing and activation of HB-EGF, transforming growth factor-α, and amphiregulin. ADAM10-deficient mice die at day 9.5 of embryogenesis with multiple defects of the developing central nervous system and cardiovascular system. ADAM10 plays a critical role during neurogenesis, in Notch signaling, and in the regulation of neuronal cell adhesion. However, the molecular function of ADAM10 in the vascular system has not been analyzed to date. The purpose of the present study was to assess the role of ADAM10 in the regulation of vascular permeability and its influence on the expression and function of the endothelial cell adhesion molecule VE-cadherin.

Materials and Methods

Sources of reagents, immunocytochemistry staining, cell culture methods, transfection methods, and statistical analysis are listed in the expanded Materials and Methods section in the online data supplement at http://circres.ahajournals.org.

Western blotting was performed as described elsewhere. Quantification of soluble VE-cadherin was performed in triplicates using Bender MedSystems (Vienna, Austria) ELISA according to the instructions of the manufacturer.

Permeability Assay

Human umbilical vein endothelial cell (HUVECs) (3×10^5) normally, 6×10^5 cells for ADAM10 overexpression or small interfering [si]RNA experiments) were seeded on collagen-coated transwell filters (0.4-μm pore size, Costar) in 24-well dishes and grown until they reached confluence. For the assay, cells were preincubated for 30 minutes in the presence of metalloprotease inhibitors GI254023X (10 μmol/L), GM6001 (10 μmol/L), or DMSO in RPMI medium 1640. Afterward, fluorescein isothiocyanate (FITC)-dextran (M, 40 000; Sigma) at a final concentration of 1 mg/mL was added to the upper chamber. At the indicated time points 50-μL samples were taken from the lower compartment and replaced with the same volume of growth medium. The fluorescent content of samples was measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm using a fluorescence plate reader (Lambda Fluoro 320, MWG Biotech.).

Preparation of Phytohemagglutinin-Stimulated T Cells

Peripheral blood mononuclear cells were isolated from buffy coat preparations from healthy volunteers and stimulated with phytohemagglutinin (PHA) (0.5 μg/mL) for four days. Viable cells were further propagated in RPMI medium 1640 in the presence of recombinant interleukin-2 (10 U/mL). After 2 days, the cells were used for transmigration assays.

Transmigration Assay

HUVECs were grown to confluence on collagen-coated transwell tissue culture inserts (Costar, Cambridge, Mass) of 3-μm pore size. PHA-stimulated T cells (PHA-blasts) were centrifuged over Ficoll to remove dead cells and debris. Cells were resuspended in endothelial cell growth medium and 5×10^5 cells added into each insert and left to migrate through the monolayers. Triplicate wells were used for each data point. After 24 hours of incubation, cells in the lower chamber were counted. Results are expressed as percentage of transmigrated cells of 3 independent counts.

Results

ADAM10 Mediates VE-Cadherin Proteolysis and Modulates Vascular Permeability

To analyze whether ADAM9, -10, or -17 are feasible candidates for VE-cadherin cleavage, we cotransfected these proteases together with a carboxy (C)-terminal hemagglutinin (HA)-tagged VE-cadherin construct in COS-7 cells. Using antibodies against the HA tag, we found that only ADAM10 overexpression increased in the generation of the VE-cadherin C-terminal fragments (CTFs) (Figure 1A).

For the analysis of VE-cadherin processing in an endogenous system, we used HUVECs. Only minor amounts of CTFs could be detected under constitutive conditions, indicating that these fragments may be substrates for further proteolysis (Figure 1B). To assess whether VE-cadherin processing is followed by intramembrane γ-secretase-mediated cleavage, VE-cadherin shedding was analyzed in the presence of the γ-secretase inhibitors DAPT or inhibitor X. The application of these inhibitors increased the amount of CTFs, indicating a role of the γ-secretase in VE-cadherin proteolysis (Figure 1B).

To clarify the involvement of the most likely candidate sheddase ADAM10 and its close homolog ADAM17 for VE-cadherin proteolysis in HUVECs, we performed inhibitor studies with 2 hydroxamate-based compounds that differ in their capacity to block the activities of these 2 proteases. The inhibitor GW280264X has been shown to block ADAM17 and ADAM10, whereas the compound GI254023X blocked ADAM10 with more than 100-fold increased potency compared to ADAM17. To avoid the rapid processing of the CTFs by γ-secretase, we included the γ-secretase inhibitor X in our assays. As shown in Figure 1C, both the VE-cadherin CTF generation (left) and the release of soluble VE-cadherin (right) could be strongly diminished by the preferential ADAM10 inhibitor GI254023X. The inhibitor led to a dose-dependent decrease of VE-cadherin proteolysis (Figure I in the online data supplement), indicating that the majority of metalloprotease-released VE-cadherin in HUVECs can be attributed to ADAM10. This result was verified using siRNA experiments. Transfection of HUVECs with ADAM10 siRNA led to an 80% reduction of ADAM10 protein expression, which resulted in a 60% reduction of VE-cadherin processing as shown in Figure 1D (see also supplemental Figure II). Because metalloproteases may also exert indirect effects by activating each other, we stimulated HUVECs with 4-aminophenyl mercuric acetate (APMA), a potent activator...
of both MMPs and ADAMs.17 APMA treatment increased VE-cadherin proteolysis only in the presence of ADAM10, indicating that ADAM10 is directly responsible for VE-cadherin shedding (supplemental Figure IIIA). Our observation that recombinant ADAM10 can cleave recombinant VE-cadherin in vitro provides additional evidence for a direct interaction of these proteins (supplemental Figure IIIB).

Endothelial cell–cell junctions control the intercellular permeability to plasma solutes, and their integrity depends on the structure and function of VE-cadherin.18,19 To analyze whether ADAM10 would affect the integrity of intercellular junctions, we measured the permeability of a confluent endothelial monolayer for 40-kDa FITC-dextran. Cells were cultivated on transwell filter inserts in the presence of the preferential ADAM10 inhibitor GI254023X or the broad-spectrum metalloprotease inhibitor GM6001. ADAM10 inhibition led to a significant decrease of endothelial permeability compared to the mock-treated cells (Figure 1E, top).

Previously, it has been described that endothelial activation by lipopolysaccharide, TNF-α, or anti-graft antibodies induced an upregulation of ADAM10 at the endothelial cell surface.20 To evaluate whether increased ADAM10 expression would also alter endothelial permeability, HUVECs were transfected either with ADAM10 or empty vector, and the endothelial permeability for FITC-dextran (40 kDa) was measured at different time points in a fluorescence plate reader (λex 485 nm; λem 525 nm) (top). HUVECs were transfected with either empty vector (1, inset) or ADAM10 (2, inset) and seeded on transwell filters. Forty-eight hours after transfection and after monolayer formation, permeability for FITC-dextran (40 kDa) was measured (bottom). One representative of 3 experiments is shown, respectively. Data are expressed as means±SD. *P<0.05: GI254023X-vs DMSO-treated cells (top); vs mock-transfected cells (bottom).

**Figure 1.** ADAM10 mediates VE-cadherin shedding and modulates endothelial permeability. A, ADAM10 overexpression increases VE-cadherin proteolysis. Cos-7 cells were cotransfected with HA-tagged VE-cadherin and empty vector (pcDNA3.1), ADAM9, ADAM10, or ADAM17. Cells were analyzed by immunoblot using anti-HA antibody (bottom). The same blot was reprobed with an anti-ADAM10 antibody. FL indicates full length; p, precursor of ADAM10; m, mature form of ADAM10. B, HUVECs were treated with DMSO, γ-secretase inhibitor X (1 μmol/L), or the γ-secretase inhibitor DAPT (10 μmol/L) for 18 hours, followed by lysis and immunoblot analysis using C-terminal VE-cadherin antibody. C, HUVECs were incubated with DMSO, ADAM10 inhibitor (GI254023X, 10 μmol/L), ADAM10/17 inhibitor (GW280264X, 10 μmol/L), or the broad-spectrum metalloprotease inhibitors TAPI (20 μmol/L) or GM6001 (10 μmol/L) for 18 hours. Cell pellets were analyzed for the generation of VE-cadherin CTFs by immunoblotting (left) and for the release of soluble VE-cadherin ectodomain by VE-cadherin ELISA (right). One representative immunoblot and a corresponding ELISA of 3 experiments are shown. ELISA data are expressed as means±SD. *P<0.05 vs DMSO-treated cells. D, HUVECs were transiently transfected with control siRNA or hADAM10 siRNA. Cell pellets were harvested 48 hours after transfection and analyzed for VE-cadherin CTF generation and ADAM10 expression by immunoblotting. Tubulin was used as loading control. E, ADAM10 modulates endothelial permeability. HUVECs were grown to confluence on porous collagen-coated transwell filters and pretreated with DMSO, GI254023X (10 μmol/L), or GM6001 (10 μmol/L) for 10 minutes. Permeability for FITC-dextran (40 kDa) was measured at different time points in a fluorescence plate reader (λex 485 nm; λem 525 nm) (top). HUVECs were transfected with either empty vector (1, inset) or ADAM10 (2, inset) and seeded on transwell filters. Forty-eight hours after transfection and after monolayer formation, permeability for FITC-dextran (40 kDa) was measured (bottom). One representative of 3 experiments is shown, respectively. Data are expressed as means±SD. *P<0.05: GI254023X-vs DMSO-treated cells (top); vs mock-transfected cells (bottom).
stimulation. Therefore, we set out to assess which stimuli may activate ADAM10-mediated VE-cadherin shedding. Previously, Herren et al showed that serum starvation–induced endothelial apoptosis correlates with a dramatic decrease of VE-cadherin at the cell surface.7 When HUVECs were deprived of growth factors for 16 hours in the presence or absence of the ADAM10 inhibitor GI254023X, we found that VE-cadherin CTF formation did not significantly increase (Figure 2A). This became even more apparent when shedding was calculated as the percentage of VE-cadherin CTFs in relation to total VE-cadherin (full-length protein and VE-cadherin fragment) by densitometric quantification of 3 experiments. In contrast, staurosporine, a general protein kinase inhibitor, which is also well known to induce endothelial cell apoptosis,21 significantly increased ADAM10-dependent VE-cadherin proteolysis (Figure 2B). This effect was rather attributable to the apoptotic signaling cascade than to protein kinase C (PKC) inhibition because 2 PKC inhibitors, GF109203X and GÖ6976, did not affect VE-cadherin shedding (supplemental Figure IV).

ADAM-mediated shedding of diverse membrane proteins occurs in response to PKC activation by phorbol esters like phorbol 12-myristate 13-acetate (PMA). PKC activation has also been discussed to influence endothelial permeability,21 but, to date, the results in HUVECs have been conflicting. Whereas Yamada et al22 showed that activation of PKC caused a decrease in endothelial permeability, Bussolino et al23 found an increase in endothelial permeability. As shown in Figure 3A, PMA stimulation of HUVECs did not result in increased VE-cadherin proteolysis, suggesting that ADAM10-mediated VE-cadherin processing is independent of PKC activation.

Endothelial dysfunction can be induced by several vasoactive substances but also by Ca²⁺ ionophores such as ionomycin, which are known to elevate endothelial permeability.21 Ionomycin stimulation strongly increased the generation of VE-cadherin CTFs, and this effect was abrogated in the presence of the preferential ADAM10 inhibitor GI254023X (Figure 3B) or by ADAM10 siRNA transfection (supplemental Figure VA). Stimulation with ionomycin also led to loss of VE-cadherin from the cell surface (Figure 3C). Accordingly, cells lost cell–cell contacts and exhibited a slightly rounded appearance. In contrast, cotreatment with the ADAM10 inhibitor GI254023X retained VE-cadherin at the cell surface and prevented gap formation. This observation confirms our biochemical data and strongly suggests that ADAM10-dependent changes in VE-cadherin localization and endothelial cell–cell adhesion can be induced by Ca²⁺ influx.

Thrombin Stimulation Leads to ADAM10-Mediated VE-Cadherin Shedding

Thrombin induces endothelial permeability by stimulation of cytoskeletal signaling pathways, resulting in an increase of intracellular Ca²⁺.24 To test whether thrombin induces VE-cadherin proteolysis, HUVECs were stimulated with thrombin for 5 to 120 minutes and analyzed by Western blot analysis. Thrombin rapidly induced VE-cadherin CTF formation (Figure 4A). This effect started 5 minutes after stimulation and was maximal after 10 minutes. This increase was abolished in the presence of a broad-spectrum
metalloprotease inhibitor or by ADAM10 siRNA transfection (Figure 4B and supplemental Figure VB), suggesting that thrombin leads to an ADAM10-mediated VE-cadherin proteolysis.

Thrombin stimulation also induced a rapid increase in endothelial permeability, which was sustained for 1 hour (Figure 4C). Preincubation with the preferential ADAM10 inhibitor GI254023X reduced the constitutive shedding and led to 40% reduction of the thrombin effect. Nevertheless, thrombin also slightly induced endothelial permeability in the presence of the inhibitor, indicating that ADAM10 activity contributes to the thrombin-induced decrease of endothelial cell–cell adhesion but acts in concert with other mechanisms.

This assumption was further confirmed using immunocytochemical analyses. VE-cadherin immunoreactivity was very prominent at cell–cell junctions of mock-treated cells (Figure 4D). After 30 minutes, thrombin stimulation...
led to nearly complete loss of VE-cadherin from the cell surface and to gap formation, resulting from cell rounding and cell contraction. Even though thrombin also affected HUVECs pretreated with the ADAM10 inhibitor GI254023X, gap formation and loss of cell–cell contacts was less pronounced compared to mock-treated cells. Instead, VE-cadherin immunoreactivity was mostly preserved at cell–cell borders. Whereas mock-treated cells recovered slowly, VE-cadherin expression and cell contact formation was completely restored after 120 minutes in the presence of the ADAM10 inhibitor. These data confirm that the ADAM10 inhibitor stabilizes the surface expression of VE-cadherin and counteracts the thrombin-induced cell dissociation.

Transmigration of Activated T Cells Through Endothelial Monolayer Is ADAM10-Dependent

Activated leukocytes have to passage through the endothelial barrier before they get to the sites of inflammation.25 Migrating leukocytes induce delocalization of VE-cadherin, result-
ing in a gap through which the cells can pass. To analyze whether ADAM10 activity would affect leukocyte transmigration, HUVECs were preincubated with different metalloprotease inhibitors, and T-cell transmigration was monitored after 16 hours in a transwell system. The broad-spectrum metalloprotease inhibitor GM6001 significantly reduced transendothelial migration compared to mock-treated cells (Figure 5A). Interestingly, the preferential ADAM10 inhibitor GI254023X showed the most pronounced effect. This result was further confirmed in a similar assay using ADAM10 siRNA transfection, which led to decreased ADAM10 protein expression in HUVECs (Figure 5B, inset) and to a decreased T-cell transmigration (Figure 5B). These data demonstrate that ADAM10 activity modulates not only endothelial cell–cell adhesion but also leukocyte transmigration. To analyze whether ADAM10 activity would also be required on the surface of the transmigrating T cells, we additionally transfected the T cells with ADAM10 siRNA. As shown in Figure 5B, ADAM10 reduction in T cells also led to a decreased transmigration rate. These findings indicate that ADAM10 plays an additional role for the regulation of adhesion and migration capacities of activated human T cells.

Discussion

In this study, we have identified a critical role for ADAM10 in the regulation of vascular permeability and transendothelial T-cell migration. Our data demonstrate that ADAM10-mediated cleavage of VE-cadherin is an important mechanism to regulate endothelial cell–cell adhesion. Using HUVECs, we demonstrate here that pharmacological inhibition and siRNA knockdown of ADAM10 reduces VE-cadherin proteolysis, thus leading to increased amounts of VE-cadherin on the cell membrane and decreased vascular permeability and leukocyte transmigration.

Interestingly, our data demonstrate, for the first time, that the metalloprotease generated C-terminal VE-cadherin fragment is a substrate for regulated intramembrane proteolysis. This proteolytic sequence has been implicated in the processing of an increasing number of proteins, which are able to directly regulate signal transduction via translocation to the nucleus. For other proteins, like N-cadherin, the intramembrane cleavage has been shown to indirectly influence cell signaling by enhancing the degradation of transcription factors and β-catenin signaling. In this context, our data suggest the interesting possibility that VE-cadherin may also directly contribute to cellular signaling.

The intercellular junctions of endothelial cells have an important barrier function regulating the permeability to small molecules. VE-cadherin is critically involved in the modulation of endothelial permeability. Pharmacological inhibition of ADAM10 activity correlated with decreased paracellular permeability, as evidenced by a decreased passage of 40-kDa dextran.

Recently, it has been described that activation of endothelial cells with lipopolysaccharide or TNF-α led to upregulation of ADAM10 in endothelial cells. Together with our finding of increased endothelial permeability attributable to ADAM10 overexpression, these data indicate that misregulation of ADAM10 activity may contribute to inflammation induced changes in vascular permeability.

However, we cannot exclude that ADAM10 is additionally involved in the shedding of other endothelial cell adhesion molecules, which are also important for vascular permeability and may directly or indirectly contribute to the observed effect.

In contrast to the junctional distribution of VE-cadherin, the ADAM10 substrate N-cadherin shows a diffusive ex-
have demonstrated that through their adhesion, leukocytes but also for circulating leukocytes. Previous studies in the RhoA/Rho kinase signaling pathway, it is likely that the activation of tyrosine kinase pathway, it is likely that the activation of ADAM10 inhibitor. Because several signaling mechanisms are involved in thrombin-induced hyperpermeability, including the RhoA/Rho kinase signaling pathway or protein tyrosine kinase pathway, it is likely that the activation of ADAM10 is part of several associated thrombin effects.

The vascular endothelium forms a barrier for macromolecules but also for circulating leukocytes. Previous studies have demonstrated that through their adhesion, leukocytes could transfer intracellular signals to endothelial cells in different ways. It has been described that transmigration across endothelium resulted in dissociation and loss of the VE-cadherin complex, but the mechanism by which delocalization of VE-cadherin occurs is still unclear. Activated polymorphonuclear cell or purified polymorphonuclear cell elastase have been reported to cleave VE-cadherin. In contrast, Allport et al reported that mononuclear leukocytes, which have significantly less proteolytic capabilities as compared to neutrophils, still induce focal changes in VE-cadherin complex that correlate with the location of actively transmigrating leukocytes. These findings suggest that the loss of VE-cadherin is attributable to an endothelial-dependent mechanism.

According to our data, ADAM10 is involved in the regulation of the transmigration process by controlling endothelial cell adhesion. It is tempting to speculate that transmigrating leukocytes induce endothelial intracellular signaling that activates ADAM10-dependent VE-cadherin cleavage, leading to transient gap formation. It is noteworthy that leukocyte adhesion is also associated with an increase in intracellular Ca2+. This effect may contribute to an activation of ADAM10-dependent VE-cadherin shedding. Our results demonstrating that Ca2+ influx induces the cleavage of VE-cadherin depending on ADAM10 activity offers valuable clues to understand the disappearance of VE-cadherin and the gap formation during the transmigration process (Figure 6).

Because ADAM10, which is also expressed at the T-cell surface, has also been described to act in trans, the leukocytes may in principle also cleave off the endothelial VE-cadherin. This could be 1 explanation for our finding that ADAM10 reduction in activated T cells led to decreased transendothelial migration. On the other hand, the leukocyte adhesion and transmigration process involves several adhesion molecules, like PECAM or JAM; therefore, it is more likely that other unidentified ADAM10 substrates could be responsible for this effect. Further studies will have to show whether VE-cadherin trans-shedding is feasible or which additional proteolytic events and molecules are involved in the transmigration process (Figure 6).
In conclusion, our findings on the molecular interactions of ADAM10 and VE-cadherin help to explain an important regulatory mechanism of VE-cadherin-mediated function, such as control of paracellular permeability and leukocyte transmigration. Dysregulation of ADAM10 activity may contribute to VE-cadherin-dependent defects in vascular permeability or angiogenesis associated with diseases such as atherosclerosis or chronic edema. Future studies are required to understand how this interaction is integrated into the various signaling networks that regulate vascular permeability and leukocyte transendothelial migration.

Acknowledgments

Murine VE-cadherin expression plasmid was kindly provided by D. Vestweber. We thank Björn Ahrens for excellent technical assistance, Johanna Groth for initial experiments in an advanced student course, and Maria Sara for proofreading the manuscript.

Sources of Funding

This work was supported by Deutsche Forschungsgemeinschaft grants Sonderforschungsbereich 415, TPB9, and Cluster of Excellence “Inflammation at Interfaces” (to P.S. and K.R.); Interuniversity Attraction Poles Program P5/19 of the Belgian Federal Science Policy Office (C.P.B.); European Union grant APOPSIS LSHM-CT-2003-503330 (to C.P.B.); and NIH grant EY015719 (to C.P.B.). K.R. was supported by the Stiftung zur Förderung der medizinischen Forschung (Faculty of Medicine, University of Kiel) and the Hensel-Stiftung. A.L. was supported by 17KF Biomat and by DFG Lu 8694/1–1.

Disclosures

None.

References

ADAM10 Regulates Endothelial Permeability and T-Cell Transmigration by Proteolysis of Vascular Endothelial Cadherin

Beate Schulz, Jessica Pruessmeyer, Thorsten Maretzky, Andreas Ludwig, Carl P. Blobel, Paul Saftig and Karina Reiss

Circ Res. 2008;102:1192-1201; originally published online April 17, 2008;
doi: 10.1161/CIRCRESAHA.107.169805

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/102/10/1192

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2008/04/17/CIRCRESAHA.107.169805.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
**Expanded Materials and Methods section**

**Antibodies and reagents**

Monoclonal antibody against VE-cadherin and peroxidase-conjugated immunoglobulins to mouse or rabbit IgG were obtained from Santa Cruz Biotechnology, Inc. ADAM10 was detected using a polyclonal antiserum from Calbiochem. β-Tubulin antibody (E7) was from DSHB (University of Iowa). Goat anti-mouse IgG conjugated to Alexa Fluor 594 was from Molecular Probes. The γ-secretase inhibitors DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl esterand) and inhibitor X (L-685,458) were purchased from Calbiochem. TAPI, GM6001, CF109203X, GÖ6976, APMA (aminophenylmercuric acetate), Ionomycin, staurosporine and thrombin (from human plasma) were obtained from Sigma. Hydroxamate-based inhibitors GI254023 and GW280264 were described elsewhere. Recombinant human VE-cadherin and ADAM10 were obtained from R&D Systems.

**Cell culture and transfection**

HUVECs were obtained from Provitro and cultured in Endothelial Cell Growth Medium from PromoCell. All experiments were performed with HUVECs from passages 2-4. COS-7 cells were grown in DMEM (high glucose) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (PAA Laboratories). Murine VE-cadherin in pcDNA3.1 vector, kindly provided by D. Vestweber, was fused with C-terminally hemagglutinin (HA)-tag. COS-7 cells were transfected in six-well tissue culture plates using FuGENE 6 (Roche) according to the manufacturer’s instructions. HUVECs were transfected with jet PEI™-HUVEC transfection reagent from Polyplus transfection (Hamburg, Germany) according to manufacturer’s instructions.
siRNA transfection

Inhibition of ADAM10 expression was performed using the following RNAi oligonucleotides (Stealth™ RNAi, Invitrogen): HSS100165, HSS100166, HSS100167. Unspecific RNAi (Stealth™ RNAi Negative Control LO GC, Invitrogen) with low GC content was used as a negative control. HUVECs were transfected with a total of 40 pmol of an equimolar mixture of the three constructs. Cells were seeded on transwell filters 4 hours after transfection. The cells were harvested for immunoblot analysis after 48 hours. For downregulation of ADAM10 in human T cells (PHA blasts) 5X10⁶ cells were transfected with a total of 150 pMol of an equimolar mixture of the three constructs, using the AMAXA electroporation system according to manufacturers’ instructions. After 6 hours of incubation the medium was replaced. T cells were seeded on top of the HUVECs 24h after transfection.

Immunocytochemistry

HUVECs were grown to confluence on collagen-coated glass coverslips. Cells were incubated in serum-free RPMI with stimuli for different time points. Cells were fixed and permeabilised with methanol at –20°C for 10 min. After washing with PBS, cells were blocked with 3% BSA in PBS for 45 min and incubated with primary antibody for 1 hour at room temperature. Following washing with PBS, cells were incubated with secondary antibodies (goat anti-mouse IgG Alexa Fluor 594) for 1h.

Statistical analysis

All values are expressed as mean of triplicates ± S.D. or as mean ± standard error of the mean (SEM). The SEM values indicate the variation between mean values obtained from at least three independent experiments. The assumptions for normality (Kolmogorov-Smirnov test) and equal variance (Levene median test) were verified with the SigmaStat 3.1 software.
The analysis of variance were performed with one-way ANOVA. Multiple parametric statistical comparisons between experimental groups versus a control group were accomplished with Dunnett’s method. All pairwise multiple comparison procedures were performed with Tukey’s test. p-values < 0.05 were classified as statistically significant.

**Supplementary Figure Legends**

**Supplementary Figure 1. Dose-dependent decrease of VE-cadherin proteolysis.** HUVECs were treated with DMSO or different concentrations of ADAM10 inhibitor (GI254023X). Cell pellets were analyzed for VE-cadherin CTF generation by immunoblot. Tubulin was used as loading control.

**Supplementary Figure 2. Densitometric analysis of ADAM10 siRNA transfection and VE-cadherin proteolysis in HUVECs.** Cell pellets of untransfected, mock-transfected or ADAM10 siRNA-transfected HUVECs were harvested 48 hours after transfection and analyzed for ADAM10 expression and for VE-cadherin CTF generation by immunoblot. Total ADAM10 expression and VE-cadherin CTF generation of 4 different experiments was quantified by densitometric analysis. ADAM10 siRNA transfection significantly decreased ADAM10 expression and VE-cadherin shedding. *P<0.05 ADAM10 siRNA vs control siRNA treated cells*. 
**Supplementary Figure 3. VE-cadherin proteolysis is ADAM10-dependent.** (A) HUVECs were pretreated with DMSO or ADAM10 inhibitor GI254023X (10 µM) for 30 min. Then, cells were stimulated with APMA (100 µM), a potent activator of MMPs and ADAMs, for 30 min. Cell pellets were analyzed for VE-cadherin CTF generation by immunoblotting (upper panel). CTF generation was calculated as percentage of total VE-cadherin by densitometric analysis (right panel). Data are expressed as mean±SEM; n=4 independent experiments. *P<0.05 DMSO+APMA vs DMSO, °P<0.05 GI+APMA vs DMSO+APMA treated cells.

HUVECs were transiently transfected with control siRNA or hADAM10 siRNA (lower panel). 48 hours after transfection cells were stimulated with APMA (100 µM), for 30 min. Cell pellets were analyzed for VE-cadherin CTF generation and ADAM10 expression by immunoblotting. p: precursor of ADAM10; m: mature form of ADAM10. Tubulin was used as loading control.

B) Recombinant VE-cadherin is cleaved by ADAM10 in vitro. Recombinant VE-cadherin (1 mg, R & D Systems) was incubated with recombinant ADAM10 (100 ng, R & D Systems) in reaction buffer (25 mM Tris/0.005% Brij-35/2.5 mM ZnCl2, pH 8.8) at 37°C (10 ml per sample). Before starting the reaction, a 10-µl sample was taken, representing the intact VE-cadherin. At the indicated time points, samples were taken and immediately mixed with Laemmli buffer and analyzed by SDS/PAGE under reducing conditions. ADAM10 and VE-cadherin were analyzed by immunoblot with anti-HIS-antibodies.

**Supplementary Figure 4. PKC inhibition does not influence VE-cadherin proteolysis.** HUVECs were incubated with PKC inhibitor CF109203X (5 µM) and GÖ6976 (1 µM) over night in the presence of γ-secretase inhibitor X (1 µM). Cells were lysed and analyzed by immunoblot using anti-VE-cadherin antibody. Tubulin was used as loading control.
Supplementary Figure 5. Ionomycin and Thrombin induce ADAM10-dependent VE-cadherin shedding. HUVECs were transiently transfected with control siRNA or hADAM10 siRNA. 48 h after transfection cells were treated with A) ionomycin (IO, 10 µM) or with B) thrombin (1 U/ml) for 30 min in the presence of the γ-secretase inhibitor X (1 µM). Cells were analysed for VE-cadherin CTF generation and ADAM10 expression by immunoblotting. Tubulin was used as loading control.

REFERENCE

Supplementary Figure 1
Supplementary Figure 2
Supplementary Figure 3
Supplementary Figure 4
Supplementary Figure 5